| Source: Active Biotech AB
·         Laquinimod showed additive effect in improving renal function when
combined with the standard of care treatment
·         Results provide rationale for further studies of laquinimod in active
lupus nephritis to confirm the safety and efficacy profile observed in this

Jerusalem,  Israel  and  Lund,  Sweden,  June 12(th), 2013 - Teva Pharmaceutical
Industries  Ltd.  (NYSE:  TEVA)  and  Active  Biotech  (NASDAQ OMX NORDIC: ACTI)
announced  today the results of a Phase IIa study of oral laquinimod designed to
assess  safety, tolerability and clinical efficacy in patients with active lupus
nephritis,   one   of   the   most  serious  manifestations  of  systemic  lupus
erythematosus  (SLE  or  lupus)that  can  lead  to  chronic  kidney  failure(1).
Treatment  with  laquinimod  provided  an  additive  effect  in  improving renal
function  when combined with current standard of care for active lupus nephritis
(mycophenolate  mofetil  and  corticosteroids),  compared  with standard of care
alone.  The data will be presented during the European League Against Rheumatism
(EULAR)  Annual European Congress of Rheumatology in Madrid, 12-15 June, 2013 as
part of the late-breaking news session.

"The  favorable  trends  towards  laquinimod  treatment in the renal end-points,
coupled  with  the  safety  and  tolerability  profile,  provide a rationale for
further  Phase  III  clinical  studies,"  said  Principal Investigator Dr. David
Jayne, Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge.

"The  results  from  this  clinical  study  further our understanding of how the
immunomodulatory  profile of laquinimod  may benefit patients  with lupus," said
Dr.  Michael Hayden,  President of  Global R&D  and Chief  Scientific Officer of
Teva.  "The  development  program  for  laquinimod, which also includes clinical
studies  for  other  auto-immune  disorders  like multiple sclerosis and Crohn's
disease,  underscores  Teva's  continued  commitment  to bringing innovative and
differentiated medicines to improve patients' lives."

The  clinical  trial,  NCT01085097,  was  a  multicenter, double-blind, placebo-
controlled,  exploratory study of  46 patients with active  lupus nephritis that
evaluated  oral laquinimod (0.5 and  1mg/day) versus placebo in combination with
standard of care treatment. The study showed that at 24 weeks, 62.5% of patients
with  active lupus nephritis who received 0.5mg/day of laquinimod achieved renal
response,  compared to  33.3% of patients  who were  administered placebo. Renal
response  is a  composite end  point that  measures several  parameters of renal

Reported  adverse events (AEs) were comparable  in both the active treatment and
placebo  patient groups. Serious AEs were  reported in 12 patients (four in each
treatment  group)  and  were  attributed  to infection, thromboembolic events or
lupus-related  complications. One death occurred in the active treatment arm due
to  pan-lobar pneumonia & sepsis  in a patient with  advanced disease. The death
was not attributed to the study drug.

A  larger  clinical  trial  of  laquinimod  in combination with standard of care
(mycophenolate mofetil and corticosteroids), compared to standard of care alone,
is  planned in patients with lupus nephritis  to further evaluate the safety and
efficacy profile observed in study NCT01085097.

Lupus  is a  chronic and  often disabling  autoimmune disease. An estimated five
million  people  worldwide,  including  1.5 million  Americans,  have  a form of
lupus.(2)  Most people who are affected by  lupus are women of childbearing age,
who  suffer from symptoms including intense  fatigue and exhaustion, joint pain,
thinking  and memory problems  and skin rashes.(3)  Lupus is two  to three times
more  common among people  of African, Hispanic,  Caribbean and Asian origin.(2)
Many  patients fail to respond or respond only partially to the current standard
of care treatments.(4)

Laquinimod  is an oral, investigational, CNS-active immunomodulator with a novel
mechanism  of action  being developed  for the  treatment of relapsing-remitting
multiple sclerosis (MS). Laquinimod showed efficacy in animal models for both MS
and   Lupus  Nephritis.  The  global  Phase  III  clinical  development  program
evaluating  oral  laquinimod  in  MS  includes  two pivotal studies, ALLEGRO and
BRAVO.  A third Phase III laquinimod trial, CONCERTO, is evaluating two doses of
the  investigational product  (0.6mg and  1.2mg) in approximately 1,800 patients
for  up to 24 months.  The primary outcome  measure will be confirmed disability
progression as measured by the Expanded Disability Status Scale (EDSS).

Systemic Lupus Erythematosus (SLE) is an autoimmune disease, in which the body's
immune system turns on itself, attacking healthy tissue, which can lead to
chronic inflammation and damage to various body tissues. SLE can affect many
parts of the body, including joints, skin, kidneys, heart, lungs, blood vessels
and the brain. Although people with SLE may experience different symptoms, some
of the more common symptoms include extreme fatigue, painful or swollen joints
(arthritis), unexplained fever, skin rashes and kidney problems.(5) SLE can be
severe and life threatening.(6)

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic drugs as
well as innovative and specialty pharmaceuticals and active pharmaceutical
ingredients. Headquartered in Israel, Teva is the world's leading generic drug
maker, with a global product portfolio of more than 1,000 molecules and a direct
presence in about 60 countries. Teva's branded businesses focus on CNS,
oncology, pain, respiratory and women's health therapeutic areas as well as
biologics. Teva currently employs approximately 46,000 people around the world
and reached $20.3 billion in net revenues in 2012.

Active  Biotech AB  (NASDAQ OMX  NORDIC: ACTI)  is a  biotechnology company with
focus  on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase
are   laquinimod,   an   orally   administered   small   molecule   with  unique
immunomodulatory  properties for the  treatment of multiple  sclerosis, TASQ for
prostate  cancer and ANYARA primarily for the treatment of renal cell cancer. In
addition,  laquinimod  is  in  Phase  II  development for Crohn's and Lupus. The
company  also has  one additional  project in  clinical development,  the orally
administered    compound    57-57 for    Systemic    Sclerosis.   Please   visit for more information.

 IR        |Kevin              C.|United  States              |
 Contacts: |Mannix               |                            |(215) 591-8912
           |Tomer                |Israel                      |972 (3) 926-7656
           |Amitai               |                            |
           |                     |                            |
 PR        |Iris Beck-Codner     |Israel                      |972 (3) 926-7687
 Contacts: |                     |                            |
           |Denise Bradley       |United States               |(215) 591-8974
           |                     |                            |
           |                     |                            |
 Active    |Tomas Leanderson     |Active Biotech AB           |+46-46-19-20-95
 Biotech:  |                     |                            |
           |Hans Kolam           |Active Biotech AB           |+46-46-19-20-44

Teva's  Safe  Harbor  Statement  under  the  U. S. Private Securities Litigation
Reform Act of 1995:
This  release  contains  forward-looking  statements,  which express the current
beliefs   and   expectations   of  management.  Such  statements  are  based  on
management's  current beliefs and expectations and involve a number of known and
unknown risks and uncertainties that could cause our future results, performance
or  achievements  to  differ  significantly  from  the  results,  performance or
achievements  expressed or implied by such forward-looking statements. Important
factors  that  could  cause  or  contribute  to  such  differences include risks
relating  to: our ability to develop and commercialize additional pharmaceutical
products,  competition  for  our  innovative  products,  especially  Copaxone(®)
(including competition from innovative orally-administered alternatives, as well
as  from potential purported  generic equivalents), competition  for our generic
products  (including  from  other  pharmaceutical  companies  and as a result of
increased   governmental  pricing  pressures),  competition  for  our  specialty
pharmaceutical  businesses, our ability to  achieve expected results through our
innovative  R&D efforts, the effectiveness of  our patents and other protections
for   innovative  products,  decreasing  opportunities  to  obtain  U.S.  market
exclusivity  for  significant  new  generic  products,  our ability to identify,
consummate  and successfully  integrate acquisitions,  the effects  of increased
leverage   as  a  result  of  recent  acquisitions,  the  extent  to  which  any
manufacturing or quality control problems damage our reputation for high quality
production  and require  costly remediation,  our potential  exposure to product
liability  claims to the  extent not covered  by insurance, increased government
scrutiny  in both the  U.S. and Europe  of our agreements  with brand companies,
potential liability for sales of generic products prior to a final resolution of
outstanding patent litigation, including that relating to the generic version of
Protonix(®),  our exposure to currency fluctuations  and restrictions as well as
credit risks, the effects of reforms in healthcare regulation and pharmaceutical
pricing  and reimbursement,  any failures  to comply  with complex  Medicare and
Medicaid  reporting  and  payment  obligations, governmental investigations into
sales  and marketing  practices (particularly  for our  specialty pharmaceutical
products), uncertainties surrounding the legislative and regulatory pathways for
the  registration and approval of  biotechnology-based products, adverse effects
of political or economical instability, corruption, major hostilities or acts of
terrorism  on our significant worldwide  operations, interruptions in our supply
chain  or problems with our information technology systems that adversely affect
our  complex manufacturing processes, any failure  to retain key personnel or to
attract  additional executive  and managerial  talent, the  impact of continuing
consolidation  of our distributors and customers, variations in patent laws that
may  adversely  affect  our  ability  to  manufacture  our  products in the most
efficient  manner, potentially significant impairments  of intangible assets and
goodwill,  potential increases in tax liabilities, the termination or expiration
of  governmental programs or tax benefits, environmental risks and other factors
that are discussed in our Annual Report on Form 20-F for the year ended December
31, 2012 and  in  our  other  filings  with  the  U.S.  Securities  and Exchange
Commission.  Forward-looking statements speak only as  of the date on which they
are  made  and  the  Company  undertakes  no  obligation to update or revise any
forward-looking statement, whether as a result of new information, future events
or otherwise.

Active Biotech's Safe Harbor Statement in Accordance with the Swedish Securities
Market Act:
This press release contains certain forward-looking statements. Such forward-
looking statements involve known and unknown risks, uncertainties and other
important factors that could cause the actual results, performance or
achievements of the company, or industry results, to differ materially from any
future results, performance or achievement implied by the forward-looking
statements. The company does not undertake any obligation to update or publicly
release any revisions to forward-looking statements to reflect events,
circumstances or changes in expectations after the date of this press release.

Active Biotech is obligated to publish the information contained in this press
release in accordance with the Swedish Securities Market Act. This information
was provided to the media for publication 2:00 p.m. CET on June 12, 2013.

                                     # # #

1.       MedlinePlus. National Library of Medicine National Institutes of
Health. Lupus nephritis. Available at: Accessed April
18, 2013.
2.       U.S. Department of Health and Human Services Office of Minority Health.
Lupus Data/Statistics. Available at: Accessed
April 18, 2013.
3.       Lupus Research Institute. About Lupus. Available at: Accessed April 18, 2013.
4.       Study Protocol 201; March 9, 2011; p 21.
5.       National Institutes of Health, National Institute of Arthritis and
Musculoskeletal and Skin Diseases.  Handout on Health: Systemic Lupus
Erythematosus. August 2011. Available at: Accessed April 19, 2013.
6.       Bernatsky S, Bovin J-F, Joseph L, et al. Mortality in systemic lupus
erythematosus. Arthritis Rheum 2006;54:2550-7.